Opioid switching in cancer patients

References

• Portenoy RK. Treatment of cancer pain. Lancet. 2011;377:2236–2247. DOI:10.1016/S0140-6736(11)60236-5
   PubMed Web of Science ®Google Scholar
• Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 3. Clinical strategies to improve opioid responsiveness. J Pain Symptom Manage. 2001;21:338–5.
   PubMed Web of Science ®Google Scholar
• Pasternak GW, Pan YX. Mu opioids and their receptors: evolution of a concept. Pharmacol Rev. 2013;65:1257–1317. DOI:10.1124/pr.112.007138
   PubMed Web of Science ®Google Scholar
• Pasternak GW. Opioids and their receptors: are we there yet? Neuropharmacology. 2014;76(Pt B):198–203. DOI:10.1016/j.neuropharm.2013.03.039
   PubMed Web of Science ®Google Scholar
• He L, Fong J, von Zastrow M, et al. Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell. 2002;108:271–282.
   PubMed Web of Science ®Google Scholar
• Dong YP, Liu XY, Liu RS. Switching from morphine to fentanyl affects µ-opioid receptor expression in periaquaductal gray of rats. Chin Med J (Engl). 2013;126:3712–3716.
   PubMed Web of Science ®Google Scholar
• Pasternak GW. Opiate pharmacology and relief of pain. J Clin Oncol. 2014;32:1655–1661. DOI:10.1200/JCO.2013.53.1079
   PubMed Web of Science ®Google Scholar
• Dietis N, Rowbotham DJ, Lambert DG. Opioid receptor subtypes: fact or artifact. Br J Anaesth. 2011;107:8–18. DOI:10.1093/bja/aer115
   PubMed Web of Science ®Google Scholar
• Raehal KM, Schmid CL, Groer CE, et al. Functional selectivity at the mu-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol Rev. 2011;63:1001. DOI:10.1124/pr.111.004598
   PubMed Web of Science ®Google Scholar
• Xu J, Faskowitz AJ, Rossi GC, et al. Stabilization of morphine tolerance with long-term dosing: association with selective upregulation of mu-opioid receptor splice variant mRNAs. Proc Natl Acad Sci USA. 2015;112:279–284. DOI:10.1073/pnas.1419183112
   PubMed Web of Science ®Google Scholar
• Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain. 2002;100:213–217. DOI:10.1016/S0304-3959(02)00422-0
   PubMed Web of Science ®Google Scholar
• Lee M, Silverman S, Hansen H, et al. A comprehensive review of opioid-induce hyperalgesia. Pain Phys. 2011;14:145–161.
   PubMed Web of Science ®Google Scholar
• Rios CD, Jordan BA, Gomes I, et al. G-protein-coupled receptor dimerization: modulation of receptor function. Pharmacol Ther. 2002;92:71–87. DOI:10.1016/S0163-7258(01)00160-7
   Web of Science ®Google Scholar
• Vanderah TW, Ossipov MH, Lai J, et al. Mechanisms pf opioid-induced pain and antinociceptive tolerance: descending facilitation and spinal dynorphin. Pain. 2001;92:5–9.
   PubMed Web of Science ®Google Scholar
• Tumati S, Largent-Milnes TM, Keresztes A, et al. Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist. J Neuroimmunol. 2012;244:23–31. DOI:10.1016/j.jneuroim.2011.12.021
   PubMed Web of Science ®Google Scholar
• Sjogren P, Jensen NH, Jensen TS. Disappearance of morphine-induce hyperalgesia after discontinuing or substituting morphine wuth other opioid agonists. Pain. 1994;59:313–316.
   PubMed Web of Science ®Google Scholar
• Galer BS, Coyle N, Pasternak G, et al. Individual variability in the response to different opioids: report of five cases. Pain. 1992;49:87–91.
   PubMed Web of Science ®Google Scholar
• De Stoutz N, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage. 1995;10:378–384.
   PubMed Web of Science ®Google Scholar
• Mercadante S. Switching methadone: a 10-year experience of 345 patients in an acute palliative care unit. Pain Med. 2012;13:399–404. DOI:10.1111/j.1526-4637.2012.01334.x
   PubMed Web of Science ®Google Scholar
• Kloke M, Rapp M, Bosse B, et al. Toxicity and/or insufficient analgesia by opioid therapy: risk factors and the impact of changing the opioid. A retrospective analysis of 273 patients observed at a single center. Support Care Cancer. 2000;8:479–486.
   PubMed Web of Science ®Google Scholar
• Reddy A, Yennurajalingam S, de la Cruz M, et al. Factors associated with survival after opioid rotation in cancer patients presenting to an outpatient supportive care center. J Pain Symptom Manage. 2014;48:92–98. DOI:10.1016/j.jpainsymman.2013.08.010
   PubMed Web of Science ®Google Scholar
• Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev. 2006;32:304–315. DOI:10.1016/j.ctrv.2006.03.001
   PubMed Web of Science ®Google Scholar
• Mercadante S, Ferrera P, Villari P, et al. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage. 2009;37:632–641. DOI:10.1016/j.jpainsymman.2007.12.024
   PubMed Web of Science ®Google Scholar
• Vissers KCP, Besse K, Hans G, et al. Opioid rotation in the management of chronic pain: what is the evidence? Pain Pract. 2010;10:85–93. DOI:10.1111/j.1533-2500.2009.00335.x
   PubMed Web of Science ®Google Scholar
• Lawlor P, Turner K, Hanson J, et al. Dose ratio between morphine and methadone in patients with cancer pain. A retrospective study. Cancer. 1998;82:1167–1173.
   PubMed Web of Science ®Google Scholar
• Parsons HA, de la Cruz M, El Osta B, et al. Methadone initiation and rotation in the outpatient setting for patients with cancer pain. Cancer. 2010;15:520–528.
   Web of Science ®Google Scholar
• Benítez-Rosario MA, Salinas-Martín A, Aguirre-Jaime A, et al. Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors. J Pain Symptom Manage. 2009;37:1061–1068. DOI:10.1016/j.jpainsymman.2008.05.016
   PubMed Web of Science ®Google Scholar
• Chatham MS, Dodds Ashley ES, Svengsouk JS, et al. Dose ratios between high dose oral morphine of equivalents and oral methadone. J Palliat Med. 2013;16:947–950. DOI:10.1089/jpm.2012.0434
   PubMed Web of Science ®Google Scholar
• Morley JS, Watt JWG, Wells JC, et al. Methadone in pain uncontrolled by morphine. Lancet. 1993;342:1243. DOI:10.1016/0140-6736(93)92228-L
   PubMed Web of Science ®Google Scholar
• Mercadante S, Casuccio A, Calderone L. Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol. 1999;17:3307–3312.
   PubMed Web of Science ®Google Scholar
• Benítez-Rosario MA, Feria M, Salinas-Martín A, et al. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain. Cancer. 2004;101:2866–2873. DOI:10.1002/cncr.v101:12
   PubMed Web of Science ®Google Scholar
• Mercadante S, Bianchi M, Villari P, et al. Opioid plasma concentration during switching from morphine to methadone: preliminary data. Support Care Cancer. 2003;11:326–331.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Valle A, Porzio G, et al. Opioid switching in patinets with advanced cancer followed at home. A retrospective analysis. J Pain Symptom Manage. 2013;45:298–304. DOI:10.1016/j.jpainsymman.2012.02.025
   PubMed Web of Science ®Google Scholar
• Ross JR, Riley J, Quigley C, et al. Clinical pharmacology and pharmacotherapy of opioid switching in cancer patients. Oncologist. 2006;11:765–773. DOI:10.1634/theoncologist.11-7-765
   PubMed Web of Science ®Google Scholar
• Riley J, Ross JR, Rutter D, et al. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer. 2006;14:56–64. DOI:10.1007/s00520-005-0843-2
   PubMed Web of Science ®Google Scholar
• Gagnon B, Bruera E. Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain. J Pain Symptom Manage. 1999;18:120–125.
   PubMed Web of Science ®Google Scholar
• Prommer E. Rotating methadone to other opioids: a lesson in the mechanisms of opioid tolerance and opioid-induced pain. J Palliat Med. 2006;9:488–493. DOI:10.1089/jpm.2006.9.488
   PubMed Web of Science ®Google Scholar
• Walker PW, Palla S, Pei BL, et al. Switching from methadone to a different opioid: what is the equianalgesic dose ratio? J Palliat Med. 2008;11:1103–1108. DOI:10.1089/jpm.2007.0285
   PubMed Web of Science ®Google Scholar
• Reddy A, Yennurajalingam S, Pulivarthi K, et al. Frequency, outcome, and predictors of success within 6 weeks of an opioid rotation among outpatients with cancer receiving strong opioids. Oncologist. 2013;18:212–220.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Bruera E. Opioid switching in cancer pain: from the beginning to nowadays. Crit Rev Oncol Hematol. 2016;99:241–248. DOI:10.1016/j.critrevonc.2015.12.011
   PubMed Web of Science ®Google Scholar
• Mercadante S, Ferrera P, Casuccio A. Outcome of opioid switching 4 weeks after discharge from a palliative care unit. Curr Med Res Opin. 2011;27:2357–2360. DOI:10.1185/03007995.2011.635197
   PubMed Web of Science ®Google Scholar
• Reddy A, Yennurajalingam S, Reddy S, et al. The Opioid Rotation Ratio From Transdermal Fentanyl to “Strong” Opioids in Patients With Cancer Pain. J Pain Symptom Manage. 2016;51:1040–1045
   PubMed Web of Science ®Google Scholar
• Reddy A, Tayjasanant S, Haider A, et al. The opioid rotation ratio of strong opioids to transdermal fentanyl in cancer patients. Cancer. 2016;122:149–156. DOI:10.1002/cncr.29688
   PubMed Web of Science ®Google Scholar
• McLean S, Twomey F. Methods of rotation from another strong opioid to methadone for the management of cancer pain: a systematic review of the available evidence. J Pain Symptom Manage. 2015;50:248–259. DOI:10.1016/j.jpainsymman.2015.02.029
   PubMed Web of Science ®Google Scholar
• González-Barboteo J, Alentorn XG, Manuel FA, et al. Effectiveness of opioid rotation in the control of cancer pain: the ROTODOL study. J Opioid Manag. 2014;10:395–403. DOI:10.5055/jom.2014.0236
   PubMedGoogle Scholar
• Reddy A, Yennurajalingam S, Desai H, et al. The opioid rotation ratio of hydrocodone to strong opioids in cancer patients. Oncologist. 2014;19:1186–1193. DOI:10.1634/theoncologist.2014-0130
   PubMed Web of Science ®Google Scholar
• Reddy A, Yennurajalingam S, Pulivarthi K, et al. Frequency, outcome, and predictors of success within 6 weeks of an opioid rotation among outpatients with cancer receiving strong opioids. Oncologist. 2013;18:212–220. DOI:10.1634/theoncologist.2012-0269
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain. 1990;43:273–286.
   PubMed Web of Science ®Google Scholar
• Dale O, Moksnes K, Kaasa S. European palliative care research collaborative pain guidelines: opioid switching to improve analgesia or reduce side effects. A systematic review. Palliat Med. 2011;25:494–503. DOI:10.1177/0269216310384902
   PubMed Web of Science ®Google Scholar
• Mercadante S, Caraceni A. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Pall Med. 2011;25:494–503. DOI:10.1177/0269216311406577
   PubMed Web of Science ®Google Scholar
• Fine PG, Portenoy RK; Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation. Establishing “best practices” for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage. 2009;38:418–425. DOI:10.1016/j.jpainsymman.2009.06.002
   PubMed Web of Science ®Google Scholar
• Ossipov MH, Lai J, Vanderah TW, et al. Induction of pain facilitation by sustained opioid exposure: relationship to opioid antinociceptive tolerance. Life Sci. 2003;73:783–800.
   PubMed Web of Science ®Google Scholar
• Chang G, Chen L, Mao J. Opioid tolerance and hyperalgesia. Med Clin N Am. 2007;91:199–211. DOI:10.1016/j.mcna.2006.10.003
   PubMed Web of Science ®Google Scholar
• Mercadante S, Ferrera P, Villari P, et al. Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manage. 2003;26:769–775.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Arcuri E. Hyperalgesia and opioid switching. Am J HospPalliat Care. 2005;22:291–294. DOI:10.1177/104990910502200411
   Google Scholar
• Hagen N, Swanson R. Strychnine-like mutifocal myoclonus and seizures in extremely high-dose opioid administration: treatment strategies. J Pain Symptom Manage. 1997;14:51–58. DOI:10.1016/S0885-3924(97)00001-8
   PubMed Web of Science ®Google Scholar
• Silverman SM. Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician. 2009;12:679–684.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Ferrera P, Arcuri E, et al. Opioid-induced hyperalgesia after rapid titration with intravenous morphine: switching and re-titration to intravenous methadone. Ann Palliat Med. 2012;1:10–13. DOI:10.3978/j.issn.2224-5820.2012.01.02
   PubMedGoogle Scholar
• Ostgathe C, Voltz R, Van Aaaken A, et al. Practicability, safety, and efficacy of a “German model” for opioid conversion to oral levo-methadone. Support Care Cancer. 2012;20:2105–2110. DOI:10.1007/s00520-011-1320-8
   PubMed Web of Science ®Google Scholar
• Webster LR, Fine PG. Overdose deaths demand a new paradigm for opioid rotation. Pain Med. 2012;13:571–574. DOI:10.1111/j.1526-4637.2012.01356.x
   PubMed Web of Science ®Google Scholar